基于国家知识产权局数据库冠心病中成药配伍规律研究
发布时间：2019-06-29 14:31
【摘要】：研究目的 研究冠心病中成药的配伍规律。 研究方法 检索中华人民共和国国家知识产权局2004-2014年冠心病中成药专利,采用双人双机独立录入Microsoft Excle2010表格,将相异率控制在3%以下,主要采用频数计数法进行统计分析。 结果 冠心病中成药最常用的单味中药为丹参(53.88%)、川芎(38.60%)、三七(34.84%)、黄芪(30.82%)、红花(25.31%)、当归(23.81%)；最常用的药对为丹参-川芎(27.07%)、丹参-黄芪(21.80%)、丹参-三七(21.55%)、丹参-红花(17.54%)、川芎-黄芪(17.29%)；最常用的角药为丹参-川芎-黄芪(12.78%)、丹参-川穹-红花(12.28%)、丹参-川芎-三七(11.28%)、丹参-川芎-当归(11.28%)、川芎-黄芪-当归(9.77%)。 结论 冠心病中成药配伍有规律可循。提示今后研发冠心病中成药应优先选用活血、补气、补血类中药；单味药优先选用丹参、川芎、三七等；药对优先选用丹参-川芎、丹参-黄芪等；角药优先选用丹参-川芎-黄芪、丹参-川穹-红花等,进而为研发新的高效的中成药提供了一定的依据。
[Abstract]:Objective to study the compatibility of proprietary Chinese medicine for coronary heart disease (CAD). Methods the patent of proprietary Chinese medicine for coronary heart disease was searched by the State intellectual property Office of the people's Republic of China from 2004 to 2014. The Microsoft Excle2010 table was input independently by double computers, and the difference rate was controlled below 3%. The frequency counting method was mainly used for statistical analysis. Results the most commonly used traditional Chinese medicine for coronary heart disease were Salvia miltiorrhiza (53.88%), Ligusticum chuanxiong (38.60%), Panax notoginseng (34.84%), Astragalus membranaceus (30.82%), safflower (25.31%) and Angelica sinensis (23.81%). The most commonly used drugs were Radix Salviae Miltiorrhiza-Ligusticum chuanxiong (27.07%), Radix Salviae Miltiorrhiza-Astragalus (21.80%), Salvia miltiorrhiza-Panax notoginseng (21.55%), Salvia miltiorrhiza-safflower (17.54%) and Ligusticum chuanxiong-Astragalus membranaceus (17.29%). The most commonly used horn drugs were Salvia miltiorrhiza-Ligusticum chuanxiong-Astragalus membranaceus (12.78%), Salvia miltiorrhiza-Chuanqiong-safflower (12.28%), Salvia miltiorrhiza-Ligusticum chuanxiong-Panax notoginseng (11.28%), Radix Rhizoma Chuanxiong-Angelica (11.28%) and Ligusticum chuanxiong-Astragalus membranaceus-Angelica sinensis (9.77%). Conclusion the compatibility of proprietary Chinese medicine in coronary heart disease can be followed regularly. It is suggested that in the future, priority should be given to activating blood circulation, invigorating qi and replenishing blood circulation, giving priority to salvia miltiorrhiza, Ligusticum chuanxiong, Panax notoginseng, etc.; giving priority to salvia miltiorrhiza, Ligusticum chuanxiong, Radix Astragali, etc.; giving priority to Radix Salviae Miltiorrhiza, Ligusticum chuanxiong, Salvia miltiorrhiza and safflower, etc., which provides a certain basis for the research and development of new and efficient proprietary Chinese medicines.
【学位授予单位】：北京中医药大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R289.1
本文编号：2507890
[Abstract]:Objective to study the compatibility of proprietary Chinese medicine for coronary heart disease (CAD). Methods the patent of proprietary Chinese medicine for coronary heart disease was searched by the State intellectual property Office of the people's Republic of China from 2004 to 2014. The Microsoft Excle2010 table was input independently by double computers, and the difference rate was controlled below 3%. The frequency counting method was mainly used for statistical analysis. Results the most commonly used traditional Chinese medicine for coronary heart disease were Salvia miltiorrhiza (53.88%), Ligusticum chuanxiong (38.60%), Panax notoginseng (34.84%), Astragalus membranaceus (30.82%), safflower (25.31%) and Angelica sinensis (23.81%). The most commonly used drugs were Radix Salviae Miltiorrhiza-Ligusticum chuanxiong (27.07%), Radix Salviae Miltiorrhiza-Astragalus (21.80%), Salvia miltiorrhiza-Panax notoginseng (21.55%), Salvia miltiorrhiza-safflower (17.54%) and Ligusticum chuanxiong-Astragalus membranaceus (17.29%). The most commonly used horn drugs were Salvia miltiorrhiza-Ligusticum chuanxiong-Astragalus membranaceus (12.78%), Salvia miltiorrhiza-Chuanqiong-safflower (12.28%), Salvia miltiorrhiza-Ligusticum chuanxiong-Panax notoginseng (11.28%), Radix Rhizoma Chuanxiong-Angelica (11.28%) and Ligusticum chuanxiong-Astragalus membranaceus-Angelica sinensis (9.77%). Conclusion the compatibility of proprietary Chinese medicine in coronary heart disease can be followed regularly. It is suggested that in the future, priority should be given to activating blood circulation, invigorating qi and replenishing blood circulation, giving priority to salvia miltiorrhiza, Ligusticum chuanxiong, Panax notoginseng, etc.; giving priority to salvia miltiorrhiza, Ligusticum chuanxiong, Radix Astragali, etc.; giving priority to Radix Salviae Miltiorrhiza, Ligusticum chuanxiong, Salvia miltiorrhiza and safflower, etc., which provides a certain basis for the research and development of new and efficient proprietary Chinese medicines.
【学位授予单位】：北京中医药大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R289.1
【参考文献】
相关期刊论文 前10条
1 苏雁涛;;诌议三七[J];当代医学;2009年13期
2 何耀,李良寿,万志恒,李兰荪,郑笑莲,贾国良;冠心病危险因素的病例对照研究[J];解放军预防医学杂志;1992年06期
3 王振涛;韩丽华;朱明军;张淑娟;曹生海;;川芎嗪注射液促心梗后大鼠缺血心肌血管新生作用及对相关生长因子影响的研究[J];辽宁中医杂志;2006年07期
4 王南，蔡海江，朱宇，陈秀英;丹参素对牛主动脉平滑肌细胞氧化修饰LDL的抑制作用[J];南京医科大学学报;1994年04期
5 陈文垲，难波恒雄，，鸟取冢和生;三种东川芎提取物的抗血小板聚集作用[J];南京中医药大学学报;1995年04期
6 张晓星;龚恬;张立平;;冠心病从肾论治[J];新中医;2008年05期
7 杨玉霞,吴卫,郑有良;红花研究进展[J];四川农业大学学报;2004年04期
8 张京春;谢元华;;陈可冀院士辨治冠心病医案的数据挖掘[J];世界中西医结合杂志;2008年01期
9 任耀龙;王永刚;郑刚;;补肾法治疗中老年冠心病机理探析[J];山西中医;2013年07期
10 王鹏;冠心病心绞痛辨证论治研究的现状及分析[J];中国中医药信息杂志;1997年05期
本文编号：2507890
本文链接：https://www.wllwen.com/falvlunwen/zhishichanquanfa/2507890.html
